Purchase a Historical Document.
A copy of the article submitted to the New England Journal of Medicine Representative of 35 years of independent research. A MUST HAVE!
Price is $100
Elephant Open Investment, LTD (EOIL) is a UK-based company. The purpose of EOIL is to provide financial leadership in the Bio-Medical-Science (BMS) sectors of governments throughout the world. The initial corporate focus of EOIL is to provide an investment vehicle to energize and transform the BMS industrial research complex. The investment strategy of EOIL will focus on three major diseases: Sickle Cell Anemia, Advanced Cancers, and Auto Immune Diseases. This investment strategy will be implemented by initiating a number of strategic processes to satisfy the dynamic and ever-changing needs of diverse governments and sovereign nations in a global environment, including, but not limited to creating, marketing, distributing and promoting value-added, exclusive financial goods, services, technologies and ideas.
Sickle Cell Market
Why our work is needed?
According to Iyer, J. (2023) with STAT News, says that “the expectation of two new sickle cell treatments (therapies) will cost more than $2 million per patient, in line with U.S. prices for existing gene therapies for other diseases of $1 million to $3.5 million.
Prices of this magnitude are unsustainable if gene therapy is to move beyond treating just a handful of patients”. Click here to read the full article.
Prices of this magnitude are unsustainable if gene therapy is to move beyond treating just a handful of patients”. Click here to read the full article.
Drugs.com shared the following information about drugs used for Anemia – Sickle Cell: “Oxbryta (voxelotor) is a member of the miscellaneous uncategorized agents drug class and is commonly used for Anemia – Sickle Cell. The cost for Oxbryta oral tablet 300 mg is around $12,044 for a supply of 60 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans”. Click here to learn more.
By investing in EOIL, you are investing in tomorrow.
You are investing to fight a battle for equality and justice.
You are investing to fight a battle for equality and justice.
The cost of the current global healthcare model is unsustainable. Elephant Open Investment, Ltd (ELEPHANT) has the potential to dramatically transform the inefficiencies (time and cost of drug development due to toxicities related to the old model). In a particular inspired innovation, Elephant has access to technologies and techniques designed to reduce the inefficiencies of the current drug development model in tandem with pressing global needs and demands for cost reduction, increase in efficiency and other smart initiatives.
The transition to this new paradigm could be relatively seamless because of the potentiating prospect of a new therapeutic class of drugs(medicines).
Elephant is driven to be a major player in a niche market that is projected to expand exponentially and rapidly because of global demand.
Elephant is seeking equity financing with an eye toward an expeditious IPO. Elephant is very aware that inadequate financing and no financing are not very far apart.
Elephant is well-positioned to become a dominant player in the modern global healthcare market through discipline, cutting-edge technological and economic innovation.
While there are multiple approaches to capturing emerging-market consumers, the two critical factors are speed and scale. Elephant is also focusing on the end-clients’ benefit through the development of unique diagnostic testing instruments.
This goal is audacious! Elephant seeks to grow deliberately and exponentially over the next 3-5 years with the global economy providing substantial diversification and opportunity to earn above-market returns through active management as well as, providing investors with handsome returns along the way.
With financial backing, Elephant will bridge new markets. The results will be superior economic returns, financial success, and an ability of Elephant to enlarge its global footprint.